Home » Stocks » SELB

Selecta Biosciences, Inc. (SELB)

Stock Price: $3.46 USD 0.10 (2.98%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $3.45 -0.01 (-0.29%) Jul 23, 7:58 PM
Market Cap 391.65M
Revenue (ttm) 27.65M
Net Income (ttm) -73.85M
Shares Out 110.74M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE 69.93
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $3.46
Previous Close $3.36
Change ($) 0.10
Change (%) 2.98%
Day's Open 3.42
Day's Range 3.31 - 3.60
Day's Volume 981,402
52-Week Range 1.47 - 5.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

COHU, NTRB, HELE, CNR, and SELB have been added to the Zacks Rank #5 (Strong Sell) List on July 14, 2021

Other stocks mentioned: CNR, COHU, HELE, NTRB
1 week ago - Zacks Investment Research

WATERTOWN, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

2 weeks ago - GlobeNewsWire

WATERTOWN, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

1 month ago - GlobeNewsWire

WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

1 month ago - GlobeNewsWire

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -83.33% and 60.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Selecta Biosciences (NASDAQ:SELB) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were down 4.76% year over year to ($0.22), which missed the es...

2 months ago - Benzinga

WATERTOWN, Mass., May 13, 2021 (GLOBE NEWSWIRE) --  Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

2 months ago - GlobeNewsWire

It may be time to buy Twitter, Inc. (NYSE:TWTR), Selecta Biosciences, Inc. (NASDAQ:SELB), and FARO Technologies, Inc. (NASDAQ:FARO) and the reasons why will be outlined below. Twitter is oversold and at...

Other stocks mentioned: FARO, TWTR
2 months ago - Benzinga

WATERTOWN, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...

2 months ago - GlobeNewsWire

The progress of one of the company's clinical programs is being delayed.

2 months ago - The Motley Fool

Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc (AskBio) has decided to give all rights of methylmalonic acidemia (MMA) to Selecta Biosciences ...

2 months ago - Benzinga

– Methylmalonic Acidemia (MMA) program to become wholly-owned by Selecta –

2 months ago - GlobeNewsWire

WATERTOWN, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...

3 months ago - GlobeNewsWire

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 6.67% and 105.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st...

4 months ago - Zacks Investment Research

- First-in-human dose-escalation study to evaluate ability of ImmTOR™  to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 -

4 months ago - GlobeNewsWire

Selecta Biosciences, Inc. (SELB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...

4 months ago - GlobeNewsWire

WATERTOWN, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...

4 months ago - GlobeNewsWire

- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector -

5 months ago - GlobeNewsWire

– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy –

5 months ago - GlobeNewsWire

Allogene Therapeutics (NASDAQ: ALLO) shares are trading higher Tuesday after Stifel upgraded the stock from Hold to Buy and raised its price target from $33 to $43 per share. Allogene is a U.S.-based cl...

Other stocks mentioned: NVS, SEEL, ALLO
5 months ago - Benzinga

- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to AAV8 alone –

6 months ago - GlobeNewsWire

WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...

6 months ago - GlobeNewsWire

Selecta was down due to unclear results from the COMPARE trial. Management attributes poor data to noncompliance due to covid-19, among other things.

7 months ago - Seeking Alpha

SHENYANG, China, Nov. 23, 2020 /PRNewswire/ -- Chinese leading biopharmaceutical company, 3SBio Inc.(01530.HK, the "Company"), announced today that Selecta Biosciences, Inc. (Nasdaq: SELB), the Company'...

8 months ago - PRNewsWire

The FDA bestows an orphan drug status on Selecta's (SELB) gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia. The candidate already has a Rare Pediatric Disease tag.

8 months ago - Zacks Investment Research

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Selecta (SELB) beat estimates for both earnings and revenues in the third quarter of 2020.

8 months ago - Zacks Investment Research

WATERTOWN, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc.  (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...

8 months ago - GlobeNewsWire

WATERTOWN, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based o...

8 months ago - GlobeNewsWire

In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.

8 months ago - Zacks Investment Research

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

Other stocks mentioned: APTX, VBIV
8 months ago - The Motley Fool

Selecta Biosciences (SELB) news for Monday includes insider buying from a Board of Directors member sending SELB stock higher. The post Selecta Biosciences News: SELB Stock Shoots 9% Higher on Insider B...

8 months ago - InvestorPlace

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: TACO, FAF, TBK
8 months ago - Benzinga

The FDA bestows a Rare Pediatric Disease status on Selecta's (SELB) gene therapy candidate MMA-101, which is being developed for the treatment of isolated methylmalonic acidemia.

9 months ago - Zacks Investment Research

These are the stocks seeing the most insider buying this week

YouTube video

In his weekly exclusive for Worldwide Exchange, Brian Sullivan highlights three stocks seeing the most insider buying this week, including some biotech names.

Other stocks mentioned: GOSS, MDT
9 months ago - CNBC Television

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: ESI, AVO, CCXX, IMNM, LUNG
9 months ago - Benzinga

Application of ImmTOR™  plus IGAN’s IgA p rotease to target immunoglobulin A ( IgA ) deposition, the critical event leading to IgA N ephropathy ( IgAN )

9 months ago - GlobeNewsWire

With a market cap of $171 million (10/1/2020), Selecta Biosciences is a well positioned clinical-stage biotech company, focusing on immunogenicity.

9 months ago - Seeking Alpha

Shares of Horizon Therapeutics PLC (NASDAQ: HZNP), which focuses on rare and rheumatic diseases, surged higher Thursday despite an absence of announcements from the biopharma. What Happened: Horizon sha...

Other stocks mentioned: HZNP
9 months ago - Benzinga

Disappointing phase 2 data casts doubt on SEL-212's future.

9 months ago - The Motley Fool

STOCKHOLM and WATERTOWN, Mass., Sept. 30, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced topline data for the p...

9 months ago - PRNewsWire

All data consistent with stronger performance of SEL-212 versus pegloticase

9 months ago - GlobeNewsWire

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies base...

10 months ago - GlobeNewsWire

STOCKHOLM and WATERTOWN, Mass., Sept. 23, 2020 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commencement of the ...

10 months ago - PRNewsWire

STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commen...

10 months ago - GlobeNewsWire

WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies base...

10 months ago - GlobeNewsWire

Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -153.13% and -100.00%, respectively, for the quarter ended June 2020.

11 months ago - Zacks Investment Research

Selecta Biosciences (SELB) miss estimates for earnings and revenues in the second quarter of 2020.

11 months ago - Zacks Investment Research

About SELB

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropat... [Read more...]

Industry
Biotechnology
IPO Date
Jun 22, 2016
CEO
Carsten Brunn
Employees
43
Stock Exchange
NASDAQ
Ticker Symbol
SELB
Full Company Profile

Financial Performance

In 2020, SELB's revenue was $16.60 million, an increase of 148.57% compared to the previous year's $6.68 million. Losses were -$68.88 million, 24.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for SELB stock is "Buy." The 12-month stock price forecast is 8.13, which is an increase of 134.97% from the latest price.

Price Target
$8.13
(134.97% upside)
Analyst Consensus: Buy